MetaTrader
  • Markets
  • Charts & Ideas
  • Algo
  • News
  • Store
  • Brokers
  • Download
  • Economic Calendar
  • Trading Signals
  • WebTerminal
  • English English
  • Русский Русский
  • 中文 中文
  • Español Español
  • 日本語 日本語
  • Deutsch Deutsch
  • 한국어 한국어
  • Français Français
  • Italiano Italiano
  • Türkçe Türkçe
Ascendis Pharma A/S American Depositary Shares

ASND

#7008
Ascendis Pharma A/S American Depositary Shares
233.5000
+5.33%
Sector:
Base:
Profit Currency:
Daily Range
233.5000
233.6600
Year Range
188.0711
242.0000
Daily Change
+5.33%
Monthly Change
-2.17%
6 month change
+13.86%
Year Change
+13.86%
Previous Close
221.6900
Open
233.6600
Bid
Ask
Low
233.5000
High
233.6600
Volume
47
  1. Markets
  2. US Stock Market
  3. Healthcare
  4. ASND
Open full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
Value Q4, 24Q4, 25 TTM

News

Investing Investing
ASND
ontem, 23:03
FDA aprova tratamento semanal da Ascendis para acondroplasia
Investing Investing
ASND
ontem, 23:01
FDA approves Ascendis’ once-weekly achondroplasia treatment
Investing Investing
ASND MP
2026.02.23
Ascendis Pharma agenda reunião anual e divulga relatórios de 2025
Investing Investing
ASND MP
2026.02.23
Ascendis Pharma schedules annual meeting and releases 2025 reports
Investing Investing
ASND
2026.02.23
RBC Capital reitera classificação das ações da Ascendis Pharma com impulso do Yorvipath
Investing Investing
ASND
2026.02.23
RBC Capital reiterates Ascendis Pharma stock rating on Yorvipath momentum
Investing Investing
ASND BBIO
2026.02.12
Cantor Fitzgerald eleva preço-alvo das ações da Ascendis Pharma para US$ 300 com base nas perspectivas da franquia CNP
Investing Investing
ASND BBIO
2026.02.12
Cantor Fitzgerald raises Ascendis Pharma stock price target to $300 on CNP franchise outlook
Investing Investing
ASND
2026.02.12
Stifel eleva preço-alvo das ações da Ascendis Pharma para US$ 325 com crescimento do Yorvipath
Investing Investing
ASND
2026.02.12
Stifel raises Ascendis Pharma stock price target to $325 on Yorvipath growth
Investing Investing
BMRN FOLD ASND BBIO
2026.02.12
Baird mantém classificação neutra para ações da BioMarin após dados positivos de concorrente
Investing Investing
BMRN FOLD ASND BBIO
2026.02.12
Baird maintains BioMarin stock rating amid competitor’s positive trial data

Markets

  • US Stock Market
  • Currencies
  • Cryptocurrencies
  • Metals
  • Commodities

Charts & Ideas

  • Trading Ideas
  • Education Ideas
  • Charts

MQL5 Community

  • Market
  • Signals
  • Forum
  • Articles
  • CodeBase

News

  • US Stock Market
  • Currencies
  • Cryptocurrencies
  • Metals
  • Commodities

Brokers

  • All Brokers
  • Forex
  • Stock
  • Metals
MetaTrader 5
MQL5 Channels
Economic Calendar
Disclaimer and Risk Disclosure Terms of Use Contacts and Requests Legal
Copyright 2000-2026, MetaQuotes Ltd